Department of Biochemistry & Molecular Medicine, UC Davis School of Medicine, Sacramento, CA, 95817, USA.
Appl Microbiol Biotechnol. 2019 Aug;103(15):6107-6117. doi: 10.1007/s00253-019-09934-5. Epub 2019 Jun 11.
Noncoding RNAs (ncRNAs), including microRNAs (miRNAs), small interfering RNAs (siRNAs), and long noncoding RNAs (lncRNAs), regulate target gene expression and can be used as tools for understanding biological processes and identifying new therapeutic targets. Currently, ncRNA molecules for research and therapeutic use are limited to ncRNA mimics made by chemical synthesis. We have recently established a high-yield and cost-effective method of producing bioengineered or biologic ncRNA agents (BERAs) through bacterial fermentation, which is based on a stable tRNA/pre-miR-34a carrier (~ 180 nt) that accommodates target small RNAs. Nevertheless, it remains a challenge to heterogeneously express longer ncRNAs (e.g., > 260 nt), and it is unknown if single BERA may carry multiple small RNAs. To address this issue, we hypothesized that an additional human pre-miR-34a could be attached to the tRNA/pre-miR-34a scaffold to offer a new tRNA/pre-miR-34a/pre-miR-34a carrier (~ 296 nt) for the accommodation of multiple small RNAs. We thus designed ten different combinatorial BERAs (CO-BERAs) that include different combinations of miRNAs, siRNAs, and antagomirs. Our data showed that all target CO-BERAs were successfully expressed in Escherichia coli at high levels, greater than 40% in total bacterial RNAs. Furthermore, recombinant CO-BERAs were purified to a high degree of homogeneity by fast protein liquid chromatography methods. In addition, CO-BERAs exhibited strong anti-proliferative activities against a variety of human non-small cell lung cancer cell lines. These results support the production of long ncRNA molecules carrying different warhead small RNAs for multi-targeting which may open avenues for developing new biologic RNAs as experimental, diagnostic, and therapeutic tools.
非编码 RNA(ncRNA),包括 microRNA(miRNA)、小干扰 RNA(siRNA)和长非编码 RNA(lncRNA),可调控靶基因的表达,并可作为了解生物过程和鉴定新治疗靶点的工具。目前,用于研究和治疗的 ncRNA 分子仅限于化学合成的 ncRNA 模拟物。我们最近建立了一种通过细菌发酵生产生物工程或生物 ncRNA 制剂(BERA)的高产、经济有效的方法,该方法基于稳定的 tRNA/miR-34a 载体(180nt),可容纳靶标小 RNA。然而,异源表达更长的 ncRNA(例如>260nt)仍然是一个挑战,并且尚不清楚单个 BERA 是否可以携带多个小 RNA。为了解决这个问题,我们假设可以将另一个人源 miR-34a 附加到 tRNA/miR-34a 支架上,提供一个新的 tRNA/miR-34a/miR-34a 载体(296nt),用于容纳多个小 RNA。因此,我们设计了十种不同的组合 BERA(CO-BERA),包括不同组合的 miRNA、siRNA 和 antagomir。我们的数据表明,所有目标 CO-BERA 都能在大肠杆菌中高水平表达,在总细菌 RNA 中的比例大于 40%。此外,重组 CO-BERA 可通过快速蛋白液相色谱法高度均一地纯化。此外,CO-BERA 对多种人非小细胞肺癌细胞系表现出强烈的抗增殖活性。这些结果支持携带不同弹头小 RNA 的长 ncRNA 分子的生产,用于多靶点靶向,这可能为开发新的生物 RNA 作为实验、诊断和治疗工具开辟途径。